Human Drugs Continue to Be Increasingly Used in Veterinary Setting, States CBR Pharma Insights in Its Report Available at

13 Jun 2016 • by Natalie Aster

LONDON – Factors such as dearth of approved animal therapies, convenience and the soaring costs of veterinary research are driving veterinarians to apply human drugs in the treatment of animals, mainly cats, dogs and horses.

The major drivers of extra-label drug use (ELDU) in animals are financial. As distinct from the human drugs scape, veterinary hospitals are engaged not only in medical diagnosis and treatment, but also enjoy the right to dispense pet meds. Consumers cannot purchase the prescribed meds from a pharmacy of their choice, where there would have access to low-cost generics, and human treatments can possibly be a viable option.

However, there are ethical, legal, safety, and health issues related to ELDU in animals. For example, prescribing a human drug for veterinary use has its own risks as mammalian species have some differences observed at a cellular level, indicating responses may vary.

A large number of veterinary med makers are seeking products that are already licensed for human use to fill the pipelines. Zoetis, Merck/MSD Animal Health, Elanco (Eli Lilly), Boehringer Ingelheim Vetmedica, and Merial (Sanofi) are the entrenched players in the marketplace.

Topical research study “Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs” elaborated by CBR Pharma Insights examines global commercial trends and prospects for human medications (or crossover drugs) used in veterinary settings.

The report covers ELDU, its application in the veterinary settings and other regulatory and procedural guidelines followed by animal health industry professionals. It provides deep insights into the rationale for some human drug products to be transitioned to the vet setting alongside disease overviews, competing therapies, information on manufacturers, finished dosage forms, therapy cost and other comprehensive marketing information. An analysis of game-changing drivers and restraints pertaining to the crossover drugs market is included. The study reviews a diverse range of marketed human medicines used in companion animals. It includes extensive profiles of major animal health industry players with diversified portfolios of crossover drugs and strategies employed by the rivals to use human therapies in the veterinary domain. Furthermore, the report identifies emerging firms marketing different crossover drugs across a set of therapeutic areas.

More studies by the publisher can be found at CBR Pharma Insights page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970